Normal Variants and Pitfalls of 18F_FDG PET/CT in Pediatric Oncology

NCT06612567 | Not Yet Recruiting

• 1 other identifier: Pitfalls PET/CT In pediatric
• Study Type: observational
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

Detection Normal variants and pitfalls of 18\_F \_FDG PET/CT imaging in pediatic oncology.

Conditions

Pitfalls of PET Scan on Pediattic

Outcome Measures

Primary Outcomes (1)

• Detection normal variants and pitfalls of 18F-FDG PET/CT Imaging in Pediatric oncology that interfere in PET/CT study results and interpretation.

  Detection normal variants and pitfalls of 18F-FDG PET/CT Imaging in Pediatric oncology that interfere in PET/CT study results and interpretation by follow up with PET/CT or other imagining or clinically

  Baseline

Interventions

PET/CT DIAGNOSTIC_TEST

is an imaging test that can help reveal the metabolic or biochemical function of your tissues and organs. The PET scan uses a radioactive drug called a tracer to show both typical and atypical metabolic activity. A PET scan can often detect the atypical metabolism of the tracer in diseases before the disease shows up on other imaging tests, such as computerized tomography (CT) and magnetic resonance imaging (MRI).

Eligibility Criteria

• Age: Up to 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Pediatric patients that will underwent PET/CT scan

You may qualify if:

• All Pediatric Cancer patients referred to nuclear medicine unit to do 18F-FDG PET/CT study.
• All patients \> or = 18 years.

You may not qualify if:

• Severely ill patients. Patients with glucose level \< 200 mg/dl.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (4)

• https://doi.org/10.3389/fnume.2022.825891

  BACKGROUND

• Smith CS, Schoder H, Yeung HW. Thymic extension in the superior mediastinum in patients with thymic hyperplasia: potential cause of false-positive findings on 18F-FDG PET/CT. AJR Am J Roentgenol. 2007 Jun;188(6):1716-21. doi: 10.2214/AJR.06.0552.

  PMID: 17515398 BACKGROUND

• Bicakci N, Elli M. 18Fluorine-fluorodeoxyglucose PET/CT Imaging in Childhood Malignancies. Mol Imaging Radionucl Ther. 2021 Feb 9;30(1):18-27. doi: 10.4274/mirt.galenos.2020.64436.

  PMID: 33586403 BACKGROUND

• Vali R, Alessio A, Balza R, Borgwardt L, Bar-Sever Z, Czachowski M, Jehanno N, Kurch L, Pandit-Taskar N, Parisi M, Piccardo A, Seghers V, Shulkin BL, Zucchetta P, Lim R. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0. J Nucl Med. 2021 Jan;62(1):99-110. doi: 10.2967/jnumed.120.254110.

  PMID: 33334912 BACKGROUND

MeSH Terms

Interventions

Positron Emission Tomography Computed Tomography

Intervention Hierarchy (Ancestors)

Positron-Emission Tomography; Tomography, Emission-Computed; Image Interpretation, Computer-Assisted; Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis; Tomography, X-Ray Computed; Multimodal Imaging; Radiographic Image Enhancement; Image Enhancement; Photography; Radiography; Tomography, X-Ray; Radionuclide Imaging; Tomography; Diagnostic Techniques, Radioisotope

Central Study Contacts

Amira Atef Mohamed, Resident doctor

CONTACT

+20 1017064445; ameraatef781@gmail.com

Waleed Ahmed Diaab, Ass.prof

CONTACT

+201004242213; Waleed.diab@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr

Study Record Dates

• First Submitted: September 22, 2024
• First Posted: September 25, 2024
• Study Start: October 1, 2024
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: September 25, 2024

Record last verified: 2024-09